[go: up one dir, main page]

WO2006113925A3 - Composition et utilisation de phyto-percolate pour le traitement d'une maladie - Google Patents

Composition et utilisation de phyto-percolate pour le traitement d'une maladie Download PDF

Info

Publication number
WO2006113925A3
WO2006113925A3 PCT/US2006/015302 US2006015302W WO2006113925A3 WO 2006113925 A3 WO2006113925 A3 WO 2006113925A3 US 2006015302 W US2006015302 W US 2006015302W WO 2006113925 A3 WO2006113925 A3 WO 2006113925A3
Authority
WO
WIPO (PCT)
Prior art keywords
phyto
percolate
disease
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/015302
Other languages
English (en)
Other versions
WO2006113925A2 (fr
Inventor
Tiffany Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zivo Bioscience Inc
Original Assignee
Health Enhancement Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/013375 external-priority patent/WO2005112987A2/fr
Application filed by Health Enhancement Products Inc filed Critical Health Enhancement Products Inc
Priority to CA002625818A priority Critical patent/CA2625818A1/fr
Priority to EP06758513A priority patent/EP1928247A4/fr
Priority to US12/067,735 priority patent/US8586053B2/en
Publication of WO2006113925A2 publication Critical patent/WO2006113925A2/fr
Priority to US11/606,676 priority patent/US7807622B2/en
Publication of WO2006113925A3 publication Critical patent/WO2006113925A3/fr
Anticipated expiration legal-status Critical
Priority to US12/897,574 priority patent/US8791060B2/en
Priority to US14/558,516 priority patent/US10166270B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention se rapporte de manière générale à un procédé de préparation d'un phyto-percolate qui est dérivé d'un mélange à base d'eau fraîche contenant des algues. Cette invention se rapporte également à l'utilisation de ce phyto-percolate pour traiter divers états pathologiques. Ce phyto-percolate est supposé présenter une activité qui induit la réduction de la fibrine soluble et de la fibrine insoluble. En outre, on suppose que ce phyto-percolate réduit le stress oxydatif dans le corps.
PCT/US2006/015302 2004-04-23 2006-04-20 Composition et utilisation de phyto-percolate pour le traitement d'une maladie Ceased WO2006113925A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002625818A CA2625818A1 (fr) 2005-04-20 2006-04-20 Composition et utilisation de phyto-percolate pour le traitement d'une maladie
EP06758513A EP1928247A4 (fr) 2005-04-20 2006-04-20 Composition et utilisation de phyto-percolate pour le traitement d'une maladie
US12/067,735 US8586053B2 (en) 2005-09-21 2006-04-20 Composition and use of phyto-percolate for treatment of disease
US11/606,676 US7807622B2 (en) 2004-04-23 2006-11-30 Composition and use of phyto-percolate for treatment of disease
US12/897,574 US8791060B2 (en) 2004-04-23 2010-10-04 Composition and use of phyto-percolate for treatment of disease
US14/558,516 US10166270B2 (en) 2004-04-23 2014-12-02 Composition and method for affecting cytokines and NF-κB

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
USPCT/US2005/13375 2005-04-20
PCT/US2005/013375 WO2005112987A2 (fr) 2004-04-23 2005-04-20 Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie
US71902505P 2005-09-21 2005-09-21
US60/719,025 2005-09-21
US74177405P 2005-12-02 2005-12-02
US60/741,774 2005-12-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/013375 Continuation-In-Part WO2005112987A2 (fr) 2004-04-23 2005-04-20 Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2005/013375 Continuation-In-Part WO2005112987A2 (fr) 2004-04-23 2005-04-20 Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie
US11/606,676 Continuation-In-Part US7807622B2 (en) 2004-04-23 2006-11-30 Composition and use of phyto-percolate for treatment of disease
AU2006320264A Division AU2006320264A1 (en) 2005-04-20 2006-12-04 Composition and use of phyto-percolate for treatment of disease

Publications (2)

Publication Number Publication Date
WO2006113925A2 WO2006113925A2 (fr) 2006-10-26
WO2006113925A3 true WO2006113925A3 (fr) 2007-06-14

Family

ID=37115978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/015302 Ceased WO2006113925A2 (fr) 2004-04-23 2006-04-20 Composition et utilisation de phyto-percolate pour le traitement d'une maladie

Country Status (2)

Country Link
EP (1) EP1928247A4 (fr)
WO (1) WO2006113925A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807622B2 (en) 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
US8586053B2 (en) 2005-09-21 2013-11-19 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
WO2008040516A2 (fr) * 2006-10-02 2008-04-10 Georg Fritzmeier Gmbh & Co. Kg Composition microbiologique et son utilisation
CA2827401A1 (fr) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents et mecanismes de traitement de l'hypercholesterolemie
US10232028B2 (en) 2013-06-13 2019-03-19 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
EP3258948B1 (fr) 2015-02-16 2023-12-06 Zivo Bioscience, Inc. Compositions anti-inflammatoires et immunomodulatoires comprenant klebsormidium et utilisations de celles-ci
CA3014897C (fr) 2016-02-16 2020-12-29 Zivo Bioscience, Inc. Soutien nutritionnel d'animaux par administration d'un supplement a base d'algues

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6723326B1 (en) * 1997-04-18 2004-04-20 Ganeden Biotech, Inc. Topical compositions containing probiotic Bacillus bacteria, spores, and extracellular products and uses thereof
US6733751B2 (en) * 1999-08-26 2004-05-11 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2564466A1 (fr) * 2004-04-23 2005-12-01 Health Enhancement Products, Inc. Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723326B1 (en) * 1997-04-18 2004-04-20 Ganeden Biotech, Inc. Topical compositions containing probiotic Bacillus bacteria, spores, and extracellular products and uses thereof
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6733751B2 (en) * 1999-08-26 2004-05-11 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1928247A4 *

Also Published As

Publication number Publication date
EP1928247A4 (fr) 2009-10-28
WO2006113925A2 (fr) 2006-10-26
EP1928247A2 (fr) 2008-06-11

Similar Documents

Publication Publication Date Title
WO2005069865A3 (fr) Derives de pyrrolopyrimidine et analogues et utilisation dans le traitement et la prevention de maladies
WO2006097793A3 (fr) Compositions capables de faciliter la penetration a travers une barriere biologique
WO2006034373A8 (fr) Variants et variants chimiquement modifies de phenylalanine ammonia-lyase
WO2007112052A3 (fr) Formulations et méthodes destinées aux maladies ou aux pathologies liées à la perméabilité vasculaire
WO2007089611A3 (fr) Compositions et leurs utilisations dirigées contre la huntingtine
EP2275543A3 (fr) Compositions et leurs utilisations dirigées vers l'hepcidine
WO2008057459A3 (fr) Antagonistes de pcsk9
WO2008057458A3 (fr) Antagonistes de pcsk9
WO2006068729A3 (fr) Procedes et compositions pour ameliorer l'absorption de fer
MY143795A (en) Tetrahydropyridoindole derivatives
WO2009149485A3 (fr) Composés destinés au traitement des amyloïdoses
WO2005076979A3 (fr) Diagnostics et therapeutiques du cancer
WO2005113752A3 (fr) Procedes et compositions de production de cellules souches a partir de cellules souches de lignee germinale derivees de sang peripherique
WO2008039941A3 (fr) Protéine scgb3a2 utilisée en tant que facteur de croissance et qu'agent anti-apoptotique
WO2006113925A3 (fr) Composition et utilisation de phyto-percolate pour le traitement d'une maladie
WO2002067971A3 (fr) Traitement de la neovasculatisation oculaire
WO2004093563A3 (fr) Composition proteique musculaire animale fonctionnelle a faible taux de cholesterol et procede associe
WO2008066775A3 (fr) Compositions et procédés visant à réduire la graisse et à rétracter la peau
WO2007065024A3 (fr) Composition et utilisation d'un phyto-percolate pour le traitement d'une maladie
WO2005112987A3 (fr) Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie
WO2005002617A3 (fr) Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang
WO2008009868A3 (fr) Procedes et outils pour la therapie de pathologies neurodegeneratives
WO2006081516A3 (fr) Utilisation de baff pour traiter des pathologies induites par th2
WO2002069989A3 (fr) Methode de traitement pour animaux aquatiques et composition contenant un extrait de pimenta
WO2007018585A3 (fr) Procede permettant de reguler le ratio proteine-sel dans une composition a base de proteines musculaires animales et ladite composition a base de proteines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11606676

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006758513

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008532207

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2625818

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: JP

WWE Wipo information: entry into national phase

Ref document number: 12067735

Country of ref document: US